Financial Instruments and Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Dec. 30, 2016	Feb. 01, 2016	Apr. 30, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Notes receivable	$ 154.0	$ 0.0
Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration			$ 52.0
Fair value of contingent liability			$ 10.6
Senior Notes | 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage				3.50%
Senior Notes | 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage				4.75%
Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	32.7	$ 33.6
Level 3 | Secured Debt | 4.00% Term Loan
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		4.00%
Level 3 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash surrender value of life insurance	67.0	$ 67.6
Level 3 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	0.0	0.0
Level 3 | Recurring | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	126.2	124.7
Level 3 | Recurring | Stratatech
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	53.5	55.7
Level 3 | Raplixa | Recurring | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent consideration	59.3	58.9
Level 3 | PreveLeak | Recurring | Hemostasis Products
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Fair value of contingent liability	11.2	$ 11.2
Level 2 | Debentures | 8.00% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Level 2 | Debentures | 9.50% Debenture
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		9.50%
Level 2 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	4.9	$ 11.1
Level 2 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	11.2	$ 10.8
Level 1 | Senior Notes | 3.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		3.50%
Level 1 | Senior Notes | 4.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		4.75%
Level 1 | Senior Notes | 5.75% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		5.75%
Level 1 | Senior Notes | 4.88% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		4.875%
Level 1 | Senior Notes | 5.50% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		5.50%
Level 1 | Unsecured Debt | 5.625% Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Debt Instrument, Interest Rate, Stated Percentage		5.625%
Level 1 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Restricted Cash and Cash Equivalents		$ 19.1
Level 1 | Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Investments, Fair Value Disclosure	21.5	$ 22.8
Maximum | Synacthen | Questcor Pharmaceuticals, Inc.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Milestone Payment	165.0
Indemnification Agreement | Mallinckrodt Baker | Level 1 | Other Assets
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Restricted Cash and Cash Equivalents	$ 19.1